A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer.

British journal of cancer ·Vol. 92 ·No. 10 ·2005-05-23 ·Pages 1834-6

Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dagg K, Scott HR

Abstract

The value of an inflammation-based prognostic score (Glasgow Prognostic score, GPS) was compared with performance status (ECOG-ps) in a longitudinal study of patients (n=101) with inoperable non-small-cell lung cancer (NSCLC). At diagnosis, stratified for treatment, only the GPS (HR 2.32, 95% CI 1.52-3.54, P<0.001) was a significant predictor of survival. In contrast, neither the GPS nor ECOG-ps measured at 3-6 months follow-up were significant predictors of residual survival. This study confirms the prognostic value of the GPS, at diagnosis, in patients with inoperable NSCLC. However, the role of the GPS and ECOG-ps during follow-up has not been established.

MeSH Terms

Aged Carcinoma, Non-Small-Cell Lung/pathology Female Health Status Humans Inflammation/classification Lung Neoplasms/pathology Male Middle Aged Neoplasm Staging/methods Prognosis Prospective Studies Survival Analysis

Authors & Affiliations

6 authors, click to expand affiliations / ORCID

Forrest L M

University Department of Surgery, Royal Infirmary, Glasgow G31 2ER, UK.

McMillan D C

McArdle C S

Angerson W J

Dagg K

Scott H R

References (13)

13 references, click to expand

Longitudinal study of weight, appetite, performance status, and inflammation in advanced gastrointestinal cancer.
Nutr Cancer. 1999;35(2):127-9 PMID: 10693165
Clinical survival predictors in patients with advanced cancer.
Arch Intern Med. 2000 Mar 27;160(6):861-8 PMID: 10737287
Prognostic factors in advanced gastrointestinal cancer patients with weight loss.
Nutr Cancer. 2000;37(1):36-40 PMID: 10965517
Cachexia.
Ann Intern Med. 2000 Oct 17;133(8):622-34 PMID: 11033592
Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss.
Nutr Cancer. 2001;39(2):210-3 PMID: 11759282
The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer.
Br J Cancer. 2002 Jul 29;87(3):264-7 PMID: 12177792
A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss.
Br J Cancer. 1999 Feb;79(3-4):495-500 PMID: 10027319
Prognostic factors.
Hematol Oncol Clin North Am. 2004 Feb;18(1):187-201 PMID: 15005288
Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: Effects on survival, metabolism, and function.
Cancer. 2004 May 1;100(9):1967-77 PMID: 15112279
Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer.
Br J Cancer. 2004 May 4;90(9):1704-6 PMID: 15150622
A new international staging system for lung cancer.
Chest. 1986 Apr;89(4 Suppl):225S-233S PMID: 3514171
Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients.
Nutr Cancer. 1998;31(2):101-5 PMID: 9770720
Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer.
Br J Cancer. 2003 Sep 15;89(6):1028-30 PMID: 12966420

Article Info

Journal

British journal of cancer

Abbr.

Br J Cancer

ISSN

0007-0920

DOI

10.1038/sj.bjc.6602591

Published

2005-05-23

Pages

1834-6

Language

English

Region

England

NLM ID

0370635

PMCID

PMC2361776

Subset

External Links

PubMed source DOI: 10.1038/sj.bjc.6602591 PMC Full Text View journal details

Analysis Services

A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer.

Contact

WeChat Official Account